Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Intersect ENT, Inc. (XENT)

28.24   0 (0%) 12-31 19:00
Open: 28.25 Pre. Close: 28.24
High: 28.25 Low: 28.23
Volume: 0 Market Cap: 0(M)

Technical analysis

as of: 2022-11-18 4:26:28 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 32.99     One year: 38.53
Support: Support1: 28.23    Support2: 28.22
Resistance: Resistance1: 28.25    Resistance2: 32.99
Pivot: 28.23
Moving Average: MA(5): 28.23     MA(20): 28.23
MA(100): 28.23     MA(250): 27.87
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 50     %D(3): 50
RSI: RSI(14): 64.9
52-week: High: 28.25  Low: 26.75
Average Vol(K): 3-Month: 0 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ XENT ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 28.32 - 28.46 28.46 - 28.57
Low: 27.83 - 28.03 28.03 - 28.19
Close: 27.97 - 28.26 28.26 - 28.5

Company Description

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

Headline News

Thu, 17 Nov 2022
SMEs challenged to set eyes on higher productivity, new markets - Capital FM Kenya

Mon, 16 May 2022
Merger Arbitrage Mondays: Chicken Soup Acquires Redbox At A Massive Discount (CSSE) - Seeking Alpha

Fri, 13 May 2022
Medtronic (MDT) completes acquisition of Intersect ENT (XENT) - StreetInsider.com

Tue, 10 May 2022
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates - Yahoo Finance

Tue, 25 Jan 2022
Real-World Evidence Study Demonstrates Intersect ENT's PROPELĀ® Sinus Implant Reduces Healthcare Resource Utilization - Business Wire

Fri, 06 Aug 2021
Medtronic to acquire Intersect ENT in $1.1B deal - Mass Device

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. 33 (M)
Shares Float 28 (M)
% Held by Insiders 1.5 (%)
% Held by Institutions 93.5 (%)
Shares Short 3,220 (K)
Shares Short P.Month 2,030 (K)

Stock Financials

EPS -2.69
EPS Est Next Qtl -0.11
EPS Est This Year -0.62
EPS Est Next Year -0.39
Book Value (p.s.) 0.49
Profit Margin (%) -149.6
Operating Margin (%) -65.3
Return on Assets (ttm) -23.3
Return on Equity (ttm) 0
Qtrly Rev. Growth 8.6
Gross Profit (p.s.) 2.29
Sales Per Share 3.19
EBITDA (p.s.) -1.94
Qtrly Earnings Growth 0
Operating Cash Flow -59 (M)
Levered Free Cash Flow -31 (M)

Stock Valuations

PE Ratio -10.54
PEG Ratio -2.3
Price to Book value 57.63
Price to Sales 8.85
Price to Cash Flow -15.89

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.